XML 85 R53.htm IDEA: XBRL DOCUMENT v3.21.1
Restatement of Previously Issued Consolidated Financial Statements - Research and development expense (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Jun. 30, 2020
Jun. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Research and Development Expense   $ 7,386 $ 4,873 $ 4,774 $ 4,882 $ 3,563 $ 3,608 $ 3,006 $ 9,647 $ 6,614 $ 17,033 $ 10,177 $ 27,848 $ 15,059 $ 12,750
Gross Profit $ (431,114) (28,584) (15) (9,703) 7,746 4,500 6,142 (7,740) (9,718) (1,598) (38,302) 2,902 $ (469,416) 10,648 (26,004)
Restatement Adjustments                              
Cost of Revenue                           19,492 21,157
Research and Development Expense   (4,578) (4,884) (5,638) (4,459) (4,465) (5,325) (4,367) (10,522) (9,692) (15,100) (14,157)   (18,616) (21,157)
Gross Profit   $ (27,294) $ (5,091) $ (5,232) $ (5,036) $ (3,847) $ (4,479) $ (3,956) $ (10,323) $ (8,435) $ (37,617) $ (12,282)   (17,318) (28,626)
Restatement Adjustments | Sales of fuel cell systems and related infrastructure                              
Cost of Revenue                           1,121 614
Restatement Adjustments | Services performed on fuel cell systems and related infrastructure                              
Cost of Revenue                           6,986 7,954
Restatement Adjustments | Power Purchase Agreements                              
Cost of Revenue                           2,539 4,264
Revision of Research and Development Expense | Restatement Adjustments                              
Research and Development Expense                           $ (19,492) $ (21,157)